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Introduction
 
The National Institute for Clinical Excellence (NICE)
was established on the 1st April 1999 as one of a
number of new quality initiatives within the UK Na-
tional Health Service (NHS) [1]. The aims of NICE
are both ambitious and far-reaching, i.e., to promote
clinical excellence and the effective use of available
resources in the NHS in England and Wales through:
• development of guidelines for the management
of certain diseases;
• auditing of methodologies and enabling the
dissemination of these to support frontline
healthcare staff and patients; and 
• appraisal of the appropriate use of specific health
technologies (including pharmaceuticals, medi-
cal devices, diagnostic techniques, procedures
and health promotion) [2].
This paper will describe the NICE technology
appraisal process and discuss some of the key is-
sues that have arisen over its first 12 months of
existence (Table 1).
 
The Appraisal Process
 
The appraisal by NICE of both new and existing
technologies encompasses:
• clinical effectiveness;
• cost-effectiveness; and
• any wider NHS implications [2].
Although NICE is directly responsible for the ap-
praisal and dissemination components of its ap-
praisal program, topic identification does not cur-
rently lie within its direct remit. The Department of
Health (DH) and the National Assembly for Wales
(NAW) identify and select technologies for NICE
appraisal. This selection is based on one or more of
the following criteria:
• Is the technology likely to result in a significant
health benefit, taken across the NHS as a
whole, if given to all patients for whom it is in-
dicated?
• Is the technology likely to result in a significant
impact on other health-related government pol-
icies (e.g., reduction in health inequality)?
• Is the technology likely to have a significant
impact on NHS resources (financial or other) if
given to all patients for whom it is indicated?
• Is NICE likely to be able to add value by issu-
ing national guidance? For instance, in the ab-
sence of such guidance is there likely to be sig-
nificant controversy over the interpretation or
significance of the technology?
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This governmental identification process is sup-
ported by input from the NHS National Horizon
Scanning and National Prescribing Centres [3].
The Institute’s appraisal of each technology can be
summarized as five key processes—scoping, assess-
ment, appraisal, consultation (and appeal) and dis-
semination. The timing of these processes is shown
in Figure 1.
 
Scoping
 
A key stage in a health technology assessment is the
definition of the precise question to be addressed [4].
Once a technology has been referred by the DH and
NAW, the Institute scopes the technology appraisal
question by defining the population, the interven-
tion (and comparator) and the outcome(s) [5].
Three key stakeholders are then invited to make
a written submission to the Institute on the basis of
this technology question. These stakeholders are:
1) national patient groups; 2) national professional
groups; and 3) the manufacturers and sponsors.
The manufacturer and sponsor submission pro-
vides an opportunity to submit both published and
unpublished clinical and cost-effectiveness evidence
that relates to the technology. Interim guidance is
currently available on the required structure and for-
mat of their submission [2]. This guidance is cur-
rently being updated and a revised version will be
published in late 2000/early 2001.
 
Assessment
 
At the core of the Institute’s appraisal process is
production of a systematic review. These reviews
are normally commissioned through the NHS re-
search and development Health Technology As-
sessment (HTA) Program via one of four univer-
sity academic groups—the Department of Public
Health & Epidemiology, University of Birming-
ham; the NHS Center for Reviews & Dissemina-
tion; the School of Health and Related Research,
 
Table 1
 
First and second wave technology appraisal program
 
Device & indication Guidance to NHS*
Zanamivir for treatment of influenza Not recommended
Routine extraction of wisdom teeth Not recommended
Hip prostheses for total hip replacement Recommend hips with revision rate of 
 

 
10% at 10 years (or 3 year
equivalent)
Taxanes for ovarian cancer Recommended
Taxanes for breast cancer Recommended
Proton pump inhibitors Recommend appropriate usage
Liquid-based cytology for cervical screening Recommend pilot site evaluation
Stents for coronary heart disease Recommendation
Advances in hearing aids Recommend analogue aids & pilot project for digital aids
Inhaler devices for children 
 

 
5 years Recommendation of pMDIs and spacers
Rosiglitazone for Type II diabetes Recommend
Beta-interferon for multiple sclerosis Decision pending (expected October 2000)
Implantable cardioverter defibrillators for arrhythmias Decision pending (expected October 2000)
Glycoprotein IIb/IIIa inhibitors for coronary heart disease Recommend
Methylphenidate for hyperkinetic disorder in childhood Decision pending (expected October 2000)
Glatiramer for multiple sclerosis Decision pending (expected October 2000)
Laparoscopic versus open surgery for colorectal cancer & hernias Decision pending (expected November 2000)
Ribavarin & alfa-interferon for hepatitis C Decision pending (expected November 2000)
Autologous cartilage transplantation for treatment of cartilage injury Decision pending (expected November 2000)
Donepezil, rivastigamine & galantamine for Alzheimer’s disease Expected December 2000
Riluzole for motor neurone disease Expected December 2000
Cofecoxib, rofecoxib, etodolac and meloxicam for the treatment of 
skeletomuscular disease
Expected January 2000
Wound care—debriding interventions and service delivery Expected January 2001
Pioglitazone for Type II diabetes Expected February 2001
Orlistat & subtramine for obesity Expected February 2001
 
*As of 1st October 2000.
Figure 1 Timetable of technology appraisal process, taken
from http://www.nice.org.
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University of Sheffield; and the Wessex Institute for
Health Services Research, University of Southamp-
ton. A systematic review is undertaken of published
clinical evidence and economic evaluations using
standard bibliographic and data synthesis meth-
ods [6,7]. Review teams also undertake a detailed
examination of the manufacturer and sponsor sub-
missions. The manufacturer and sponsor submission
provides the opportunity to review unpublished evi-
dence often unavailable through other sources. These
reviews are normally carried out over a 6-month pe-
riod and are often referred to as rapid reviews [8].
 
Appraisal
 
Health technology assessment (HTA) is the eval-
uation of technology (drug, device or procedure)
through a synthesis and systematic review of sci-
entific evidence, the result of which contributes to
decision-making and policy [9]. This definition of
HTA recognizes that both the assessment (i.e.,
generation of an evidence base) and appraisal (i.e.,
conversion of the evidence base into national pol-
icy) are components of the NICE process.
The responsibility for technology appraisal falls
on a standing committee of independent experts
drawn from the health professions, patient-focused
organizations, health service researchers, health care
managers and the pharmaceutical industry. Mem-
bership is composed of individuals who can take
both a focussed and a broader view of the evidence
presented to them (i.e., the rapid review and the
key stakeholders’ submissions). The Committee may
also invite topic specific clinical experts and pa-
tients to its meetings; they meet in private once a
month and consider, on average, two technologies
at each meeting. In making its decisions, the com-
mittee and NICE are asked to consider the follow-
ing directions from the Secretary of State:
• the broad clinical priorities of the NHS;
• the degree of clinical need of the patients with
the condition under consideration;
• the broad balance of benefits and costs;
• guidance on resources likely to be available;
• effective use of available resources;
• and encouraging innovation.
 
Consultation
 
The Committee considers each technology twice; at
the first meeting they derive a provisional guidance
and at a second meeting the Committee reconsid-
ers their decision, culminating in a final decision
(see Fig. 1). Between the two meetings, the provi-
sional decision is shared with stakeholders during
a consultation period. This consultation phase ex-
plicitly provides the opportunity for stakeholders
to feed into the NICE final technology appraisal
decision. Following consultation and the second
Committee meeting, a NICE final guidance is then is-
sued subject to a further period during which stake-
holders can appeal the process or nature of the NICE
appraisal.
 
Dissemination
 
The technology guidance document takes a stan-
dard format, including guidance, clinical need, tech-
nology, evidence, implications for the NHS, further
research, implementation notes and clinical audit ad-
vice. The guidance is disseminated through a combi-
nation of methods. Copies of each of the technology
guidelines are made available to key senior level deci-
sion-makers within the NHS, such as Chief Execu-
tives and Medical Directors of hospital trusts and
primary care groups, Directors of Public Health, and
relevant clinical groups appropriate to the technol-
ogy. The guidance, both a patient version of the
guidance and a copy of the assessment report, is
also published on the Institute website (HTTP://
www.nice.org).
 
Issues to Date
 
At the time of writing, the Institute has issued guid-
ance on 10 health technologies (Table 1). A number
of issues have arisen during this time.
 
Regulation vs. NICE
 
NICE is independent from the licensing or regula-
tion of drugs and devices, and different in its fo-
cus. Indeed the appraisal of pharmaceuticals by
the Institute has been described as the fourth hur-
dle [10]. In other words, to be licensed a pharma-
ceutical must not only fulfill the criteria of quality,
safety and efficacy but also achieve the NICE
fourth criterion of effectiveness—both clinical and
cost-effectiveness.
There are a number of possible differences be-
tween the assessments of effectiveness and efficacy
(see Table 2).
 
Assessing Emerging Technologies
 
The evaluation of emerging technologies offers spe-
cific challenges compared to evaluation of more es-
tablished, existing technologies. The evidence base
may not be published and therefore not previously
peer-reviewed. On the other hand there is a poten-
tial for bias if such unpublished evidence is not in-
cluded [5,6]. Also, evidence may be submitted as
confidential in nature and therefore not necessar-
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ily available for full citation on publication of this
guidance. A key element of the work of NICE is to
provide an evidence-based audit trail to its guid-
ance; NICE will therefore actively negotiate with
industry to enable the release of key aspects of their
confidential data. Lastly, in phase III (efficacy) tri-
als, the comparator may be a placebo rather than
current best care and relevant patient outcomes in-
formation such as quality of life and downstream
health service resource use may not have been col-
lected. This often necessitates heavy reliance on
cost-effectiveness modelling in industry submissions
for new technologies. It will be interesting over the
coming years to observe whether more pragmatic
industry phase III trials are undertaken to provide
such effectiveness data, reducing dependence on
modelling.
 
Rapid Reviews
 
The systematic rapid review described above, un-
dertaken as part of the NICE appraisal process, is
carried out over a 6-month period. This timescale
is considerably shorter than the one to three years
often associated with a Cochrane review [8]. The
relatively short timescale ensures the timeliness of
these reviews to the decision-making process of the
Institute. However, it is crucial that a reduced ti-
mescale should not compromise the quality of re-
views. The term rapid review is a rather misleading
one and in fact intensive review is a better descrip-
tion, reflecting the intensive coordinated effort that
goes into a review by multidisciplinary academic
teams. However, there remains little empirical evi-
dence comparing the quality and outcome of rapid
vs. full reviews.
 
Conclusion
 
Although a relatively young organization, its first
technology appraisal of the flu drug Relenza put
NICE firmly on the international HTA map. Twelve
technology appraisals later, and with some 40–50
technology appraisals expected over the next 12
months (a number of which will be drugs), the world-
wide interest in NICE is only likely to grow.
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Table 2
 
Comparsion of clinical efficacy versus clinical effectiveness
 
Efficacy Effectiveness
Trial type Explanatory Pragmatic
Study population Usually highly selected populations Usually few exclusions
Comparator Often placebo Often current (best) practice
Outcomes Usually clinical, morbidity, mortality and adverse effects Often patient-focused (e.g., quality of life) and 
down stream resources
